Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a(1) receptor) antagonist

The novel oral complement factor 5a receptor 1 antagonist ACT‐1014‐6470 was well tolerated in single‐ and multiple‐ascending dose studies, including 24 h Holter electrocardiogram (ECG) recordings evaluating its cardiodynamics based on data from single doses of 30–200 mg and twice‐daily (b.i.d.) dosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Anliker‐Ort, Marion, Hsin, Chih‐hsuan, Krause, Andreas, Pfister, Marc, van den Anker, John, Dingemanse, Jasper, Kaufmann, Priska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357345/
https://www.ncbi.nlm.nih.gov/pubmed/37470156
http://dx.doi.org/10.1002/prp2.1112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357345/
https://www.ncbi.nlm.nih.gov/pubmed/37470156
http://dx.doi.org/10.1002/prp2.1112

Ejemplares similares